Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2001 1
2007 1
2008 1
2010 6
2011 4
2013 2
2014 4
2015 1
2016 5
2017 3
2018 6
2019 9
2020 8
2021 5
2022 6
2023 6
2024 6
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND; EMBARK Study. Freedland SJ, et al. Among authors: gotto gt. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Management algorithms for metastatic prostate cancer.
Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So AI, Park-Wyllie L, Hew H, McLeod D, Gotto G. Malone S, et al. Among authors: gotto g. Can Urol Assoc J. 2020 Feb;14(2):50-60. doi: 10.5489/cuaj.5840. Can Urol Assoc J. 2020. PMID: 31039111 Free PMC article. Review.
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Kalac M, Sridharan S, Rosales M, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Wang F, Freedland SJ. Shore ND, et al. Among authors: gotto gt. N Engl J Med. 2025 Oct 19. doi: 10.1056/NEJMoa2510310. Online ahead of print. N Engl J Med. 2025. PMID: 41124201
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Özgüroğlu M, Pereira de Santana Gomes AJ, Vianna K, Luo H, Gotto GT, Cheng HH, Kim W, Varela CR, Schaeffer D, Kramer K, Li S, Baron B, Shen F, Mundle SD, McCarthy SA, Olmos D, Chi KN, Rathkopf DE. Attard G, et al. Among authors: gotto gt. Nat Med. 2025 Oct 7. doi: 10.1038/s41591-025-03961-8. Online ahead of print. Nat Med. 2025. PMID: 41057655
Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.
Mousa A, Nguyen DD, Lalani AK, Satkunasivam R, Aminoltejari K, Hird A, Roy S, Morgan SC, Malone S, Kokorovic A, Lavallée LT, Huynh M, Shayegan B, Jiang DM, Gotto G, Breau RH, Kulkarni GS, Zlotta A, Wallis CJD. Mousa A, et al. Among authors: gotto g. Cancer. 2025 Jan 1;131(1):e35606. doi: 10.1002/cncr.35606. Epub 2024 Oct 13. Cancer. 2025. PMID: 39396120 Free PMC article.
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.
Gotto GT, Yip SM, Shayegan B, O'Sullivan DE, Wallis CJD, Basappa NS, Cagiannos I, Hamilton RJ, Ferrario C, Fernandes R, Danielson B, Saad F, Hotte SJ, Cheung WY, Boyne DJ, Chan K, Osborne B, Zardan A, Malone S. Gotto GT, et al. Can Urol Assoc J. 2025 Jan;19(1):E25-E35. doi: 10.5489/cuaj.8691. Can Urol Assoc J. 2025. PMID: 39470659 Free PMC article.
81 results